Global PD-1 and PD-L1 Monoclonal Antibodies Supply, Demand and Key Producers, 2023-2029

Global PD-1 and PD-L1 Monoclonal Antibodies Supply, Demand and Key Producers, 2023-2029

The global PD-1 and PD-L1 Monoclonal Antibodies market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

According to the different tumor immune mechanisms, the most studied immunotherapy currently mainly includes cellular immunotherapy and immune checkpoint inhibitor therapy. Among them, the immune checkpoint inhibitor that can be used clinically has cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T lymphocyte-associated antigen 4). ' lymphocyte associated antigen-4, CTLA-4) and programmed cell death protein-1 (programmed cell death protein-1, PD-1)/programmed cell death-ligand 1 (programmed cell death-ligand 1, PD- L1). This report studies PD-1 and PD-L1 monoclonal antibodies.

This report studies the global PD-1 and PD-L1 Monoclonal Antibodies demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for PD-1 and PD-L1 Monoclonal Antibodies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of PD-1 and PD-L1 Monoclonal Antibodies that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global PD-1 and PD-L1 Monoclonal Antibodies total market, 2018-2029, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: PD-1 and PD-L1 Monoclonal Antibodies total market, key domestic companies and share, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies revenue by player and market share 2018-2023, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies total market by Type, CAGR, 2018-2029, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global PD-1 and PD-L1 Monoclonal Antibodies market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Bristol-Myers Squibb, Roche, Pfizer, Astrazeneca, Novartis, Biocad, Sanofi/Regeneron Pharmaceuticals and Beigene, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World PD-1 and PD-L1 Monoclonal Antibodies market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global PD-1 and PD-L1 Monoclonal Antibodies Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Type
PD-1 Monoclonal Antibody
PD-L1 Monoclonal Antibody

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Application
Lung Cancer Treatment
Melanoma Treatment
Bowel Cancer Treatment
Other

Companies Profiled:
Merck
Bristol-Myers Squibb
Roche
Pfizer
Astrazeneca
Novartis
Biocad
Sanofi/Regeneron Pharmaceuticals
Beigene
Jiangsu Hengrui Pharmaceuticals
Innovent Biologics, Inc.

Key Questions Answered

1. How big is the global PD-1 and PD-L1 Monoclonal Antibodies market?

2. What is the demand of the global PD-1 and PD-L1 Monoclonal Antibodies market?

3. What is the year over year growth of the global PD-1 and PD-L1 Monoclonal Antibodies market?

4. What is the total value of the global PD-1 and PD-L1 Monoclonal Antibodies market?

5. Who are the major players in the global PD-1 and PD-L1 Monoclonal Antibodies market? Show more